English(EN) Akeso lung cancer drug shines in trials, boosting hopes in US$20b market

Akeso 的肺癌药物在试验中显示死亡风险降低34%

作者 PulseAugur 编辑部 · [1 个来源] · 2026-06-01 10:49

Akeso 的肺癌药物 ivonescimab 在三期临床试验中显示出显著前景，死亡风险降低了34%。该药物显示出显著的生存获益，两年后患者存活率为64.7%，而对照组为48.6%。分析师对其改变非小细胞肺癌治疗并占据全球市场相当份额的潜力感到乐观，尽管该公司股价略有下跌。 AI

排序理由公布了药物的临床试验结果。[lever_c_demoted from research: ic=1 ai=0.0]

AI 生成摘要 · Google Gemini · 来自 1 个来源。我们如何撰写摘要 →

本文如何被排名

Signal score: 0 / 100; Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket: Tool; 公布了药物的临床试验结果。[lever_c_demoted from research: ic=1 ai=0.0]
Source corroboration: Single-source cluster; Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics: other; Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance: Low; Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness: 86 days old; Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

完整方法见我们的编辑标准。

SCMP — Tech TIER_1 English(EN) · Julie Zhang · 2026-06-01 10:49

Akeso 肺癌药物试验效果显著，提振 200 亿美元市场信心

Akeso, whose drug ivonescimab was hailed as biotech’s “DeepSeek moment” amid US competition last year, announced better-than-expected clinical results showing it can treat a type of lung cancer commonly found in smokers, potentially expanding its approved uses. Analysts suggest i…